PMID- 24065119 OWN - NLM STAT- MEDLINE DCOM- 20141113 LR - 20131002 IS - 1791-3004 (Electronic) IS - 1791-2997 (Linking) VI - 8 IP - 5 DP - 2013 Nov TI - Effects of shuangtengbitong tincture on collagen‑induced arthritis in rats. PG - 1479-85 LID - 10.3892/mmr.2013.1693 [doi] AB - Shuangtengbitong tincture (STBT), a clinical prescription from the Fujian University of Traditional Chinese Medicine (TCM) Affiliated People's Hospital (Fuzhou, China), has been used in the treatment of rheumatoid arthritis (RA) for ~10 years. The aim of the current study was to con fi rm the anti-RA effect of STBT and to evaluate the potential mechanisms underlying collagen-induced arthritis (CIA) in rats. CIA model Wistar rats were induced with bovine type II collagen. The rats were immunized with CIA and were treated with STBT (0.5 and 2 ml/injection) and votalin (~1 cm/injection) continuously for ~1 month. Following treatment, the pathological sections of CIA rat joints were observed by hematoxylin and eosin staining, expression of toll-like receptor-4 (TLR4), myeloid differentiation factor 88 (MyD88) and nuclear transcription factor-kappaB (NF-kappaB) were investigated by western blot analysis and reverse transcription-polymerase chain reaction (RT-PCR) analysis. Following treatment, STBT significantly suppressed paw swelling (P<0.05) compared with the model group and increased body weight. STBT also reversed pathological changes, STBT‑treated rats showed a signi fi cant improvement of synovial hyperplasia, in fl ammatory in fi ltration, and cartilage and bone destruction. The levels of protein and mRNA expression of TLR4, MyD88 and NF-kappaB were markedly suppressed in the synovial tissue of STBT‑ and votalin-treated rats. In addition, STBT showed marked inhibition of the levels of protein and mRNA expression of TLR4, MyD88 and NF-kappaB at an STBT volume ranging between 1 and 4 ml/day, indicating that the inhibition was volume dependent. These results show that STBT inhibits CIA and may be correlated with TLR4, MyD88 and NF-kappaB expression. FAU - Xu, Wei AU - Xu W AD - Pharmacy College, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China. FAU - Li, Huang AU - Li H FAU - Chu, Kedan AU - Chu K FAU - Zhang, Yuqin AU - Zhang Y FAU - Zheng, Haiyin AU - Zheng H FAU - Huang, Mingqing AU - Huang M FAU - Zhang, Xun AU - Zhang X FAU - Chen, Lidian AU - Chen L LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130918 PL - Greece TA - Mol Med Rep JT - Molecular medicine reports JID - 101475259 RN - 0 (Collagen Type II) RN - 0 (Drugs, Chinese Herbal) RN - 0 (Inflammation Mediators) RN - 0 (Myd88 protein, rat) RN - 0 (Myeloid Differentiation Factor 88) RN - 0 (NF-kappa B) RN - 0 (RNA, Messenger) RN - 0 (Tlr4 protein, rat) RN - 0 (Toll-Like Receptor 4) SB - IM MH - Animals MH - Apoptosis/drug effects MH - Arthritis, Experimental/chemically induced/*drug therapy/metabolism MH - Blotting, Western MH - Cattle MH - Cell Proliferation/drug effects MH - Collagen Type II/*toxicity MH - *Disease Models, Animal MH - Drugs, Chinese Herbal/*pharmacology MH - Inflammation Mediators/metabolism MH - Male MH - *Medicine, Chinese Traditional MH - Myeloid Differentiation Factor 88/genetics/metabolism MH - NF-kappa B/genetics/metabolism MH - *Phytotherapy MH - RNA, Messenger/genetics MH - Rats MH - Rats, Wistar MH - Real-Time Polymerase Chain Reaction MH - Reverse Transcriptase Polymerase Chain Reaction MH - Synovial Membrane/drug effects/metabolism MH - Toll-Like Receptor 4/genetics/metabolism EDAT- 2013/09/26 06:00 MHDA- 2014/11/14 06:00 CRDT- 2013/09/26 06:00 PHST- 2013/03/12 00:00 [received] PHST- 2013/09/09 00:00 [accepted] PHST- 2013/09/26 06:00 [entrez] PHST- 2013/09/26 06:00 [pubmed] PHST- 2014/11/14 06:00 [medline] AID - 10.3892/mmr.2013.1693 [doi] PST - ppublish SO - Mol Med Rep. 2013 Nov;8(5):1479-85. doi: 10.3892/mmr.2013.1693. Epub 2013 Sep 18.